Notch Therapeutics

David Main, President and CEO
Toronto, Canada
Notch Therapeutics designs and manufactures therapeutic T-cells from pluripotent stem cells. The company has developed a proprietary platform with the potential to fully enable best-in-class commercial manufacturing of stem-cell derived T-cells. As current T-cell therapies are limited by the use of a patient’s own cells, Notch T-cells could replace existing standard-of-care therapies and pave a path to novel therapeutics to address unmet need. Built on foundational discoveries in developmental immunology and enabled by world-class bioengineering and advanced cell manufacturing teams, Notch Therapeutics is poised to be a leader in cell therapy for oncology and other diseases.

By using this website you agree to accept our Privacy Policy and Terms & Conditions